CANCER HAS NO BORDERS. NEITHER DO WE®

BeiGene
The BeiGene Story

A global biopharmaceutical innovator focused on improving treatment outcomes and patient access

BeiGene is a fully-integrated biopharmaceutical company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China’s National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception.

BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on developing novel cancer therapies where there is global unmet need.

Our broad product portfolio and pipeline include:

- 3 wholly owned late-stage oncology candidates, including one approved in the U.S. and one approved in China
- 27 Phase 3 or potentially registration-enabling trials ongoing, 60+ studies in total
- 32 clinical or commercial stage assets including seven internally developed and 25 in-licensed

BeiGene has built a strong innovative pipeline of clinical drug candidates through internal discovery and collaborations.

Transformative Collaboration with Amgen

This global strategic oncology collaboration expands access to important oncology medicines for patients in China and around the globe with:

- BeiGene commercializing three Amgen oncology products in China — XGEVA® (denosumab), KYPROLIS™ (carfilzomib), and BLINCYTO® (blinatumomab)
- Companies jointly developing 20 Amgen oncology pipeline assets globally, with BeiGene leading development in China
- Amgen investing $2.8B for a 20.5% stake in BeiGene

3,400+ employees (as of January 29, 2020)
10 offices on 4 continents
Trials in 35 countries and regions

**Investigational KRASG12C small molecule inhibitor**
- In-licensed from Amgen, rights in China

**Investigational humanized IgG1-variant monoclonal antibody against TIM-3**
- Currently being investigated in combination with tislelizumab in solid tumors

**Investigational spectrum-selective kinase inhibitor of receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER) and split family receptors (VEGFR2, KIT)**
- Currently being investigated in combination with tislelizumab in solid tumors
- In-licensed from Mirati Therapeutics, rights in Asia ex-Japan, AU, NZ

**Investigational TIGIT monoclonal antibody**
- Currently being investigated as in combination with tislelizumab in solid tumors

**Investigational small molecule Bcl-2 inhibitor**
- Currently being investigated as a monotherapy and in combination with zanubrutinib in hematologic malignancies

**Investigational HER2-targeted bispecific antibody**
- Currently being investigated in combination with tislelizumab in solid tumors
- In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ

**Investigational HER2-targeted bispecific antibody drug conjugate (ADC)**
- In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ

**Investigational PARP1 and PARP2 inhibitor**
- Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors

**Humanized IgG4 anti-PD-1 monoclonal antibody**
- Currently being investigated as a monotherapy and in combination with tislelizumab in multiple solid tumors and hematologic malignancies

**Investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities**
- Currently being investigated as a monotherapy and in combination with mirdametinib (MEK inhibitor from SpringWorks Therapeutics) in solid tumors

**Investigational small molecule inhibitor against the immune checkpoint receptor ligand PD-L1**
- Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors

**BEIGENE’S SELECTED INVESTIGATIONAL PIPELINE**

- Potent second generation small molecule inhibitor of Bruton’s tyrosine kinase
- Currently being investigated as a monotherapy and in combination with other therapies in multiple hematologic malignancies

- Humanized IgG4 anti-PD-1 monovalent antibody
- Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies

- Investigational small molecule inhibitor of PARP1 and PARP2
- Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors

- Investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities
- Currently being investigated as a monotherapy and in combination with mirdametinib (MEK inhibitor from SpringWorks Therapeutics) in solid tumors

- Investigational humanized IgG1-variant monoclonal antibody against TIM-3
- Currently being investigated in combination with tislelizumab in solid tumors
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

- China NMPA approval in R/R classical Hodgkin’s lymphoma
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

- China NMPA approvals in myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

- Investigational HER2-targeted bispecific antibody drug conjugate (ADC)
- In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ

**BEIGENE’S COMMERCIAL PRODUCT PORTFOLIO**

- U.S. FDA accelerated approval in November 2019 for relapsed/ refractory (R/R) mantle cell lymphoma

- China NMPA approval in R/R classical Hodgkin’s lymphoma

- China NMPA approval in giant cell tumor of bone
- In-licensed from Amgen, rights in China

- China NMPA approvals in R/R multiple myeloma and multiple myeloma
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

- China NMPA approval in breast cancer
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

- China NMPA approvals in myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia
- In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
BeiGene's commitment is to never compromise on the safety, compliance, or quality of our products, our research, or our services. We are focused on serving patients by delivering quality drug products that consistently meet or exceed all customer and regulatory requirements. Each BeiGene employee and partner is responsible for achieving our objectives and for looking at any opportunity where we can improve upon our high standards of performance.

BeiGene conducts its clinical trials in accordance with the regulatory requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the China National Medical Products Administration (NMPA), as applicable. Likewise, BeiGene’s own state-of-the-art manufacturing facilities, located in China, are fully compliant with Good Manufacturing Practice (GMP) requirements of the U.S., European and Chinese authorities and subject to inspection and approval by these authorities. It has also contracted with leading American and German manufacturers for production of its drug candidates.

Meet Members of Our Leadership Team

BeiGene employees are dedicated to translating groundbreaking science into quality innovative cancer therapies. With a global headcount of over 3,400 employees, more than 1,000 are devoted to global clinical development and approximately 1,000 are in commercial operation.

John V. Oyler  
Chairman, Founder & CEO  
BioDuro, Galeneo, Telephia, Genita, McKinsey & Company

Xiaodong Wang, Ph.D.  
Founder & Chairman SAB  
NIBR, National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences

Xiaobin Wu, Ph.D.  
GM of China & President  
Pfizer, Wyeth, Bayer

Jane Huang, M.D.  
CMO, Hematology  
Acerta, Genentech

Yong (Ben) Ben, M.D.  
CMO, Immuno-Oncology  
BioAtla, AstraZeneca

Eric Hedrick, M.D.  
Chief Advisor  
Genentech, Pharmacyclics, Epizyme

Josh Neiman  
Head of U.S. Commercial  
Flatiron Health, Onyx Pharmaceuticals, Genentech

Guillaume Vignon, Ph.D.  
SVP, Business Development  
Merck KGaA

Lai Wang, Ph.D.  
SVP, Head of Global Research, Clinical Operation, Biometrics & APAC Clinical Development  
Joyant Pharmaceuticals, Howard Hughes Medical Institute

Todd Yancey, M.D.  
SVP, Global Medical Affairs & New Market Development  
BioMarin, Clovis Oncology, Medivation, Onyx Pharmaceuticals

Our Commitment

BeiGene’s commitment is to never compromise on the safety, compliance, or quality of our products, our research, or our services. We are focused on serving patients by delivering quality drug products that consistently meet or exceed all customer and regulatory requirements. Each BeiGene employee and partner is responsible for achieving our objectives and for looking at any opportunity where we can improve upon our high standards of performance.
Our employees look forward to connecting with you to provide additional insight into BeiGene.

Contact us at:
888-123-4455 or info@beigene.com

www.beigene.com

@BeiGeneUSA